Akebia Therapeutics, Inc. (AKBA)

Akebia Therapeutics Statistics

Total Valuation

AKBA has a market cap or net worth of $638.21 million. The enterprise value is $720.43 million.

Market Cap	638.21M
Enterprise Value	720.43M

Important Dates

The last earnings date was Thursday, May 8, 2025, before market open.

Earnings Date	May 8, 2025
Ex-Dividend Date	n/a

Share Statistics

AKBA has 262.64 million shares outstanding. The number of shares has increased by 13.54% in one year.

Current Share Class	262.64M
Shares Outstanding	262.64M
Shares Change (YoY)	+13.54%
Shares Change (QoQ)	+10.47%
Owned by Insiders (%)	2.19%
Owned by Institutions (%)	28.47%
Float	256.89M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	2.87
Forward PS	3.24
PB Ratio	25.87
P/TBV Ratio	n/a
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Enterprise Valuation

EV / Earnings	n/a
EV / Sales	3.90
EV / EBITDA	70.62
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 2.23, with a Debt / Equity ratio of 7.96.

Current Ratio	2.23
Quick Ratio	1.92
Debt / Equity	7.96
Debt / EBITDA	12.87
Debt / FCF	n/a
Interest Coverage	-0.78

Financial Efficiency

Return on Equity (ROE)	n/a
Return on Assets (ROA)	-4.26%
Return on Invested Capital (ROIC)	-7.83%
Return on Capital Employed (ROCE)	-8.33%
Revenue Per Employee	$1.02M
Profits Per Employee	-$250,348
Employee Count	181
Asset Turnover	0.69
Inventory Turnover	1.40

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +100.83% in the last 52 weeks. The beta is 0.88, so AKBA's price volatility has been lower than the market average.

Beta (5Y)	0.88
52-Week Price Change	+100.83%
50-Day Moving Average	2.08
200-Day Moving Average	1.80
Relative Strength Index (RSI)	58.60
Average Volume (20 Days)	3,937,648

Short Selling Information

The latest short interest is 17.77 million, so 6.77% of the outstanding shares have been sold short.

Short Interest	17.77M
Short Previous Month	17.92M
Short % of Shares Out	6.77%
Short % of Float	6.92%
Short Ratio (days to cover)	2.91

Income Statement

In the last 12 months, AKBA had revenue of $184.91 million and -$45.31 million in losses. Loss per share was -$0.21.

Revenue	184.91M
Gross Profit	153.31M
Operating Income	-18.24M
Pretax Income	-40.44M
Net Income	-45.31M
EBITDA	10.20M
EBIT	-18.24M
Loss Per Share	-$0.21

Balance Sheet

The company has $113.37 million in cash and $195.60 million in debt, giving a net cash position of -$82.22 million or -$0.31 per share.

Cash & Cash Equivalents	113.37M
Total Debt	195.60M
Net Cash	-82.22M
Net Cash Per Share	-$0.31
Equity (Book Value)	24.58M
Book Value Per Share	0.09
Working Capital	112.56M

Cash Flow

In the last 12 months, operating cash flow was -$34.81 million and capital expenditures -$51,000, giving a free cash flow of -$34.87 million.

Operating Cash Flow	-34.81M
Capital Expenditures	-51,000
Free Cash Flow	-34.87M
FCF Per Share	-$0.13

Margins

Gross margin is 82.91%, with operating and profit margins of -9.86% and -24.51%.

Gross Margin	82.91%
Operating Margin	-9.86%
Pretax Margin	-24.51%
Profit Margin	-24.51%
EBITDA Margin	5.52%
EBIT Margin	-9.86%
FCF Margin	n/a

Dividends & Yields

AKBA does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-13.54%
Shareholder Yield	-13.54%
Earnings Yield	-7.10%
FCF Yield	-5.46%

Analyst Forecast

The average price target for AKBA is $6.63, which is 172.84% higher than the current price. The consensus rating is "Strong Buy".

Price Target	$6.63
Price Target Difference	172.84%
Analyst Consensus	Strong Buy
Analyst Count	4
Revenue Growth Forecast (5Y)	34.55%
EPS Growth Forecast (5Y)	n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

AKBA has an Altman Z-Score of -5.99 and a Piotroski F-Score of 2. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	-5.99
Piotroski F-Score	2